BACKGROUND INFORMATION: Previous studies have revealed that leptin may be involved in epithelial-mesenchymal transition (EMT), a crucial initiator of cancer progression to facilitate metastatic cascade, increase tumor recurrence, and ultimately cause poor prognosis. However, the underlying mechanism remains unclear. The aim of our present study was to investigate the effect of leptin on EMT of breast cancer cells and the underlying mechanism. RESULTS: Our data demonstrated that leptin significantly increased the phosphorylation of STAT3, Akt, and ERK1/2, elevated the expression of IL-8, and induced breast cancer cells to undergo EMT. The effect of leptin on IL-8 could visibly abolished by the inhibitor of PI3K LY294002. In addition, leptin-induced EMT of breast cancer cells was blocked by anti-IL-8 antibodies. Examination of the expression of ObR, leptin, IL-8 and EMT-related biomarkers in patient specimens demonstrated that malignant breast carcinoma with lymph node metastases (LNM), which represents poor prognosis, expressed higher levels of ObR, leptin, IL-8 than other types of breast cancer, and displayed more obvious EMT transversion. In vivo xenograft experiment revealed that leptin signally promoted tumor growth and metastasis and increased the expressions of IL-8 and EMT-related biomarkers. CONCLUSIONS: Our results support that leptin-induced EMT in breast cancer cells requires IL-8 activation via the PI3K/Akt signal pathway.
BACKGROUND INFORMATION: Previous studies have revealed that leptin may be involved in epithelial-mesenchymal transition (EMT), a crucial initiator of cancer progression to facilitate metastatic cascade, increase tumor recurrence, and ultimately cause poor prognosis. However, the underlying mechanism remains unclear. The aim of our present study was to investigate the effect of leptin on EMT of breast cancer cells and the underlying mechanism. RESULTS: Our data demonstrated that leptin significantly increased the phosphorylation of STAT3, Akt, and ERK1/2, elevated the expression of IL-8, and induced breast cancer cells to undergo EMT. The effect of leptin on IL-8 could visibly abolished by the inhibitor of PI3K LY294002. In addition, leptin-induced EMT of breast cancer cells was blocked by anti-IL-8 antibodies. Examination of the expression of ObR, leptin, IL-8 and EMT-related biomarkers in patient specimens demonstrated that malignant breast carcinoma with lymph node metastases (LNM), which represents poor prognosis, expressed higher levels of ObR, leptin, IL-8 than other types of breast cancer, and displayed more obvious EMT transversion. In vivo xenograft experiment revealed that leptin signally promoted tumor growth and metastasis and increased the expressions of IL-8 and EMT-related biomarkers. CONCLUSIONS: Our results support that leptin-induced EMT in breast cancer cells requires IL-8 activation via the PI3K/Akt signal pathway.
Authors: G Luboshits; S Shina; O Kaplan; S Engelberg; D Nass; B Lifshitz-Mercer; S Chaitchik; I Keydar; A Ben-Baruch Journal: Cancer Res Date: 1999-09-15 Impact factor: 12.701
Authors: Zhao Liu; Abhik Bandyopadhyay; Robert W Nichols; Long Wang; Andrew P Hinck; Shui Wang; Lu-Zhe Sun Journal: J Stem Cell Res Ther Date: 2012-02-19
Authors: Evandro de Azambuja; Worta McCaskill-Stevens; Prudence Francis; Emmanuel Quinaux; John P A Crown; Malou Vicente; Rosa Giuliani; Bo Nordenskjöld; Jorge Gutiérez; Michael Andersson; Mireia Margeli Vila; Raimund Jakesz; Jan Demol; Joanna Dewar; Armando Santoro; Ana Lluch; Steven Olsen; Richard D Gelber; Angelo Di Leo; Martine Piccart-Gebhart Journal: Breast Cancer Res Treat Date: 2010-01 Impact factor: 4.872
Authors: Martha L Slattery; Esther John; Gabriela Torres-Mejia; Mariana Stern; Abbie Lundgreen; Lisa Hines; Anna Giuliano; Kathy Baumgartner; Jennifer Herrick; Roger K Wolff Journal: PLoS One Date: 2013-05-16 Impact factor: 3.240
Authors: Laura W Bowers; Emily L Rossi; Shannon B McDonell; Steven S Doerstling; Subreen A Khatib; Claire G Lineberger; Jody E Albright; Xiaohu Tang; Linda A deGraffenried; Stephen D Hursting Journal: Mol Cancer Res Date: 2018-02-16 Impact factor: 5.852